Epidiolex 100 mg/mL Oral Solution
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lennox Gastaut Syndrome
Conditions
Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex
Trial Timeline
Feb 24, 2025 → Feb 1, 2027
NCT ID
NCT05485831About Epidiolex 100 mg/mL Oral Solution
Epidiolex 100 mg/mL Oral Solution is a pre-clinical stage product being developed by Jazz Pharmaceuticals for Lennox Gastaut Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05485831. Target conditions include Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06924827 | Approved | Recruiting |
| NCT05485831 | Pre-clinical | Recruiting |
| NCT04721691 | Phase 1 | Completed |
Competing Products
11 competing products in Lennox Gastaut Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + Perampanel | Eisai | Phase 3 | 77 |
| Rufinamide | Eisai | Pre-clinical | 23 |
| Rufinamide (E2080) + Placebo | Eisai | Phase 3 | 77 |
| Rufinamide | Eisai | Pre-clinical | 23 |
| Rufinamide | Eisai | Phase 3 | 77 |
| Rufinamide + Any other approved Antiepileptic Drug | Eisai | Phase 3 | 77 |
| ZX008 0.2 or 0.8 mg/kg/day + Matching Placebo | UCB | Phase 3 | 74 |
| Clobazam | Lundbeck | Phase 3 | 74 |
| Cannabidiol | Jazz Pharmaceuticals | Approved | 82 |
| GWP42003-P | Jazz Pharmaceuticals | Approved | 82 |
| Clemizole HCl + Placebo | Harmony Biosciences | Phase 3 | 72 |